Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of$ 0.23. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 26.09%. A quarter ago, it was expected that this company would post a loss of$ 0.17 per share when it actually produced a loss of $0.22, delivering a surprise of -29.41%. Over the last four quarters, the company has sur ...